PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
| Status: | Completed |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 1/17/2019 |
| Start Date: | September 2010 |
| End Date: | August 2015 |
Pilot Trial to Evaluate Change in Positron Emission Tomography Scanning (PET) as a Surrogate for Zoledronate (Zometa) Efficacy in Patients With Metastatic Prostate Cancer
The primary goal for this trial is to assess the change in PET scans with the administration
of zoledronate (bisphosphonate) therapy in patients with metastatic prostate cancer. It has
been established that zoledronate therapy may play a role in delaying and reducing the
incidence of skeletal events. Researchers propose to evaluate the change in the uptake value
of FMAU PET scan after the zoledronate therapy. It has been demonstrated that FMAU PET scans
can successfully demonstrate and detect bony metastatic sites in prostate cancer.
In addition, investigators would like to evaluate the change in the level of the
prostate-specific antigen (PSA) in the patient as well as outcome of bone scans.
of zoledronate (bisphosphonate) therapy in patients with metastatic prostate cancer. It has
been established that zoledronate therapy may play a role in delaying and reducing the
incidence of skeletal events. Researchers propose to evaluate the change in the uptake value
of FMAU PET scan after the zoledronate therapy. It has been demonstrated that FMAU PET scans
can successfully demonstrate and detect bony metastatic sites in prostate cancer.
In addition, investigators would like to evaluate the change in the level of the
prostate-specific antigen (PSA) in the patient as well as outcome of bone scans.
Inclusion Criteria:
- Histological diagnosis of prostate cancer
- Evidence of metastatic disease by radiologic criteria
- Bone scan within 4 weeks of starting therapy
- Creatinine within 2 weeks of registration, calculated creatinine clearance > 60ml/min.
- Minimum life expectancy of 6 months
- Willingness to have pre-therapy PET scans performed within 2 weeks after registration
and post therapy PET scan performed within 1 week after dose of Zometa (a total of 3
PET scans required)
- Calculated creatinine clearance > 50ml/min.
- No prior Zoledronate therapy
- Patients must have disease progression despite testosterone suppression
(level<50ng/ml); progression can be by rising PSA ( at least 2 values at least 2 weeks
apart) or by new lesions on scans or progression of existing lesions on CT scan.
- No concomitant systemic therapy for metastatic prostate cancer is allowed except LHRH
analogue should be continued if necessary to maintain testosterone suppression.
- No concomitant radiation therapy
- Prior RT is allowed if completed at least 2 weeks prior to registration.
- Presence of measurable or evaluable disease
- If RT has been administered, disease outside the RT port is required.
- Willingness to sign informed consent.
- Registration and willingness to sign informed consent for separate PET protocol 2335
that describes the PET scan procedure.
- Patients must have good oral hygiene which includes having a recent dental evaluation
Exclusion Criteria:
- Patients who are unable to swallow
- Patients with dental cavities that are likely to need dental extraction or root canal
treatment as management
We found this trial at
2
sites
Barbara Ann Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
Click here to add this to my saved trials
Click here to add this to my saved trials